Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Effecty vs NP2GO

Effecty
Graded #10Editorial

Higher grade

vs+4
NP2GO
Graded #23Editorial

Lower grade

The verdict

Effecty takes it — 84/100 to 80/100.

Effecty grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mid-market pricing offset by brand-name access and LegitScript verification, all 50 states.

Both are editorial reviews with no commercial relationship.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNP2GO +1
80
81
Dose & formulationEffecty +4
84
80
Clinical oversightEffecty +6
85
79
Labs & monitoringEffecty +6
84
78
FulfillmentEffecty +5
87
82
Contract termsEffecty +4
86
82
Effecty · left barNP2GO · right bar

The numbers

MetricEffectyNP2GO
WeighScore84/10080/100
GradeBB−
Scorecard rank#10#23
Semaglutide$160/mo$150/mo
Tirzepatide$240/mo$250/mo
CoverageAll 50 states40 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
RelationshipEditorialEditorial
Effecty

Graded #10 · B

Strengths

  • Brand-name access
  • LegitScript-verified, all 50 states
  • Both molecules

Where it loses points

  • Higher pricing ($160/$240)
  • Injection-only
  • Not a value leader
NP2GO

Graded #23 · B−

Strengths

  • Both molecules
  • 40-state footprint
  • Transparent listed pricing

Where it loses points

  • Not LegitScript-verified
  • Upper-mid pricing ($150/$250)
  • Not all 50 states

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard